Fig. 4From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe forest plot reveals the correlation between Evusheld administration as prophylaxis and the rate of COVID-19 infections in double-arm subgroupBack to article page